Harvard Apparatus Regenerative Technology, Inc. (HRGN) stock
Close on Oct 19, 2026Market cap $38.92MP/E –Yield –
Harvard Apparatus Regenerative Technology, Inc. grew revenue 44.6% to $982.00K over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $38.92M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $38.92M
- P/E ratio
- –
- Price to sales
- 39.64
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $982.00K
- Net income
- -$6.68M
- EPS, diluted
- -$0.39
- Book value per share
- -$0.08
- Diluted shares
- 18M
Trading
- Previous close
- $2.23
- Open
- $2.23
- Day's range
- $2.21 – $2.23
- Volume
- 730
- Average volume (20 days)
- 1,558
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.
| Period | HRGN | S&P 500 | Difference | HRGN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -1.6% | +0.6% | −2.2 pts | ||
| 3 months | +110.9% | +3.4% | +107.5 pts | ||
| Year to date | +20.3% | +13.3% | +7.0 pts | ||
| 1 year | +21.3% | +16.6% | +4.7 pts | ||
| 3 years | -48.5% | +86.4% | −134.9 pts | -19.9% | +23.1% |
| 5 years | -26.2% | +81.9% | −108.1 pts | -5.9% | +12.7% |
| 10 years | -87.6% | +318.9% | −406.4 pts | -18.8% | +15.4% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Harvard Apparatus Regenerative Technology filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- News
- News
About Harvard Apparatus Regenerative Technology
Surgical & Medical Instruments & Apparatus
Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company developing regenerative medicine therapies for disorders of the gastrointestinal system and other organs. The company operates two segments: Regenerative Biotech and Consumer Health Products. Its regenerative platform uses patient-derived stem cells seeded on temporary synthetic scaffolds to restore organs damaged by cancer, trauma, or congenital defects, with lead product candidates targeting esophageal reconstruction, colon repair, and pediatric esophageal atresia. Through its Hong Kong subsidiary, the company also markets consumer health items and dietary supplements directly to consumers via eCommerce.
Company profile, executives and historyHarvard Apparatus Regenerative Technology stock: common questions
What is Harvard Apparatus Regenerative Technology's stock price?
HRGN closed at $2.21 on Oct 19, 2026, down 0.72% on the day.
What is Harvard Apparatus Regenerative Technology's market cap?
Harvard Apparatus Regenerative Technology was worth $38.92M at the close on Oct 19, 2026: the share price times the diluted shares outstanding.
What is HRGN's P/E ratio?
Harvard Apparatus Regenerative Technology lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.39), so it has no meaningful P/E ratio.
How much revenue does Harvard Apparatus Regenerative Technology make?
Harvard Apparatus Regenerative Technology reported revenue of $982.00K for the twelve months to Jun 30, 2026, up 44.6% from a year earlier.
Does Harvard Apparatus Regenerative Technology pay a dividend?
No. Harvard Apparatus Regenerative Technology has not paid a cash dividend over the last twelve months.
How has HRGN stock performed over the past year?
Including dividends, HRGN returned +21.3% over the past year, against +16.6% for the S&P 500.
Who are Harvard Apparatus Regenerative Technology's competitors?
Companies most similar to Harvard Apparatus Regenerative Technology by business, industry and size include PETV, OSRH, ICU, PLSE, VYCO.
See a number that looks wrong?